Journal of Neural Transmission

, Volume 119, Issue 4, pp 405–414

Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase

  • Keiko Inaba-Hasegawa
  • Yukihiro Akao
  • Wakako Maruyama
  • Makoto Naoi
Basic Neurosciences, Genetics and Immunology - Original Article

Abstract

Rasagiline and (−)deprenyl (selegiline), irreversible type B monoamine oxidase (MAO-B) inhibitors, protect neuronal cells through gene induction of pro-survival Bcl-2 and neurotrophic factors in the cellular models of neurodegenerative disorders. In this paper, the role of MAO in the up-regulation of neuroprotective Bcl-2 gene by these inhibitors was studied using type A MAO (MAO-A) expressing wild SH-SY5Y cells and the transfection-enforced MAO-B overexpressed cells. Rasagiline and (−)deprenyl, and also befloxatone, a reversible MAO-A inhibitor, increased Bcl-2 mRNA and protein in SH-SY5Y cells. Silencing MAO-A expression with short interfering (si) RNA suppressed Bcl-2 induction by rasagiline, but not by (−)deprenyl. MAO-B overexpression inhibited Bcl-2 induction by rasagiline and befloxatone, but did not affect that by (−)deprenyl, suggesting the different mechanisms behind Bcl-2 gene induction by these MAO-B inhibitors. The novel role of MAO-A in Bcl-2 induction by rasagiline is discussed with regard to the molecular mechanism underlying neuroprotection by the MAO inhibitors.

Keywords

Rasagiline (−)Deprenyl Type A and B monoamine oxidase Neuroprotection Bcl-2 Gene induction 

Abbreviations

MAO-A and MAO-B

Type A and B monoamine oxidase

MAO-B SH cells

SH-SY5Y cells overexpressed MAO-B by transfection

PD

Parkinson’s disease

siRNA

Small interfering RNA

References

  1. Abu-Raya S, Tabakman R, Blaugrund E, Trembovier V, Lazaroyici P (2002) Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol 434:109–116PubMedCrossRefGoogle Scholar
  2. Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M (2002) An anti-Parkinson’s disease drug, N-propargyl-1(R)-aminoindan (rasagiline) enhances expression of antiapoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 326:105–108PubMedCrossRefGoogle Scholar
  3. Binda C, Hubalek F, Li M, Herzig Y, Sterling J, Edmondson DE, Mattevi A (2005) Binding of rasagiline-related inhibitors to human monoamine oxidases; a kinetic and crystallographic analysis. J Med Chem 48:8148–8154PubMedCrossRefGoogle Scholar
  4. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of l-deprenyl to madopar treatment in Parkinson’s disease: a longterm study. J Neural Transm 64:113–127PubMedCrossRefGoogle Scholar
  5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein dye binding. Anal Biochem 72:248–254PubMedCrossRefGoogle Scholar
  6. Chiou SH, Ku HH, Tsai TH, Lin HL, Chen LH, Chien CS, Ho LL-T, Lee CH, Chang YL (2006) Moclobemide upregulated Bcl-2 expression and induce neural stem cell differentiation into serotoninergic neurons via extracellular-regulated kinase pathway. Br J Pharmacol 148:587–598PubMedCrossRefGoogle Scholar
  7. Dagda RK, Zhu J, Chu CT (2009) Mitochondrial kinases in Parkinson’s disease: converging insights from neurotoxin and genetic models. Mitochondrion 9:289–298PubMedCrossRefGoogle Scholar
  8. De Zutter GS, Davis RJ (2001) Pro-apoptotic gene expression mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Proc Natl Acad Sci USA 98:6168–6173PubMedCrossRefGoogle Scholar
  9. Desagher S, Osen-Sand A, Nichols A, Eskes R, Monteaauit S, Lauper S, Maundrell K, Antonsson B, Martinou J-C (1999) Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 144:891–901PubMedCrossRefGoogle Scholar
  10. Ebadi M, Brown-Borg H, Ren J, Sharma S, Shavali S, ReFacy HE, Carlson EC (2006) Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr Drug Targets 7:1513–1529PubMedGoogle Scholar
  11. Ekblom J, Oreland L, Chen K, Shih JC (1998) Is there a “non-MAO” macromolecular target for L-deprenyl?: Studies on MAOB mutant mice. Life Sci 63:PL161–PL186CrossRefGoogle Scholar
  12. Finberg JP, Lamendorf I, Weinstock M, Schwartz M, Youdim MBH (1999) Pharmacology of rasagiline [N-propargyl-1R-aminoindan]. Adv Neurol 80:495–499PubMedGoogle Scholar
  13. Fitzgerald JC, Ufer C, Billett EE (2007) A link between monoamine oxidase-A and apoptosis in serum derived human SH-SY5Y cells. J Neural Transm 114:807–810PubMedCrossRefGoogle Scholar
  14. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311:467–469PubMedCrossRefGoogle Scholar
  15. Hubalek F, Binda C, Ki M, Herzig Y, Sterling J, Youdim MBH, Mattevi A, Edmondson DE (2004) Inactivation of purified human recombinant monoamine oxidase A and B by rasagiline and its analogues. J Med Chem 47:1760–1768PubMedCrossRefGoogle Scholar
  16. Hynson RMG, Kelly SM, Price NC, Ramsay RR (2004) Conformational changes in monoamine oxidase A in response to ligand binding or reduction. Biochim Biophy Acta 1472:60–66Google Scholar
  17. Kornhuber J, Konradi C, Mack-Burkhardt F, Riederer P, Heinsen H, Beckmann H (1989) Ontogenesis of monoamine oxidase-A and -B in the human brain frontal cortex. Brain Res 499:81–86PubMedCrossRefGoogle Scholar
  18. Kraml M (1965) A rapid microfluorometric determination of monoamine oxidase. Biochem Pharmacol 14:1684–1686CrossRefGoogle Scholar
  19. Kupsch A, Sautter J, Götz ME, Breithaupt W, Schwarz J, Youdim MBH, Riederer P, Gerlach M, Oertel WH (2001) Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm 108:985–1009PubMedCrossRefGoogle Scholar
  20. Magyar K, Palfi M, Tabi T, Kalasz H, Szende B, Szöko E (2004) Pharmacological aspects of (−)-deprenyl. Curr Med Chem 11:2017–2031PubMedGoogle Scholar
  21. Malorni W, Giammarioli P, Pietrangeli E, Agostinelli E, Ciaccio A, Grassili E, Mondove B (1998) Protection against apoptosis by monoamine oxidase A inhibitors. FEBS Lett 426:155–159PubMedCrossRefGoogle Scholar
  22. Maragos WF, Tillman PA, Chesnut MD, Jakel RJ (1999) Clorgyline and deprenyl attenuate striatal malonate and 3-nitropropionic acid lesions. Brain Res 834:168–172PubMedCrossRefGoogle Scholar
  23. Maruyama W, Takahashi T, Naoi M (1998) (−)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. J Neurochem 70:2510–2515PubMedCrossRefGoogle Scholar
  24. Maruyama W, Akao Y, Youdim MB, Davis BA, Naoi M (2001) Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous neurotoxin, N-methyl(R)salsolinol. J Neurochem 78:727–735PubMedCrossRefGoogle Scholar
  25. Maruyama W, Takahashi T, Youdim M, Naoi M (2002) The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 109:467–481PubMedCrossRefGoogle Scholar
  26. Maruyama W, Nitta A, Shamoto-Nagai M, Hirata Y, Akao Y, Youdim M, Furukawa S, Nabeshima T, Naoi M (2004) N-Propargyl-1-(R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor. Neurochem Int 44:393–400PubMedCrossRefGoogle Scholar
  27. Naoi M, Maruyama W (2009) Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson’s disease. Expert Rev Neurother 9:1233–1250PubMedCrossRefGoogle Scholar
  28. Naoi M, Maruyama W (2010) Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr Pharmaceu Designs 16:2799–2817Google Scholar
  29. Naoi M, Maruyama W, Akao Y, Yi H, Yamaoka Y (2006) Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. J Neural Transm (71):67–77Google Scholar
  30. Olanow CW, Rascol O, Hauser R et al (2009) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Eng J Med 361:1268–1278CrossRefGoogle Scholar
  31. Ou X-M, Chen K, Shih JC (2006) Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci USA 103:10923–10928PubMedCrossRefGoogle Scholar
  32. Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R, Swedish Parkinson Study Group (2006) Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66:1200–1206PubMedCrossRefGoogle Scholar
  33. Parkinson Study Group (1993) Effects of tocopherol and deprenyl on progression of disability in early Parkinson’s disease. N Engl J Med 328:176–183CrossRefGoogle Scholar
  34. Riederer P, Lachenmayer L, Laux G (2004) Clinical applications of MAO-inhibitors. Curr Med Chem 11:2033–2043PubMedGoogle Scholar
  35. Shacka JJ, Roth KA (2005) Regulation of neuronal cell death and neurodegeneration by members of the Bcl-2 family: therapeutic implications. Curr Drug Targets CNS Neurol Disord 4:24–39CrossRefGoogle Scholar
  36. Tatton WG, Ju WYL, Holland D, Tai C, Kwan M (1994) (−)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63:1572–1575PubMedCrossRefGoogle Scholar
  37. Tazik S, Johnson S, Lu D, Johnson C, Youdim MBH, Stockmeler CA, Ou X-M (2009) Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurotoxic Res 15:284–290CrossRefGoogle Scholar
  38. Yi H, Akao Y, Maruyama W, Chen K, Shih JC, Naoi M (2006a) Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells. J Neurochem 96:541–549PubMedCrossRefGoogle Scholar
  39. Yi H, Maruyama W, Akao Y, Takahashi T, Iwasa K, Youdim MB, Naoi M (2006b) N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J Neural Transm 113:21–32PubMedCrossRefGoogle Scholar
  40. Youdim MBH, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295–309PubMedCrossRefGoogle Scholar
  41. Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MBH, Le W (2008) Comparison of neuroprotective and neurorestorative capacities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopamine degeneration. J Neurochem 105:1970–1978PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Keiko Inaba-Hasegawa
    • 1
  • Yukihiro Akao
    • 2
  • Wakako Maruyama
    • 3
  • Makoto Naoi
    • 1
  1. 1.Department of NeurosciencesGifu International Institute of BiotechnologyKakamigaharaJapan
  2. 2.United Graduate School of Drug Discovery and Medical Information SciencesGifu UniversityGifuJapan
  3. 3.Department of Cognitive Brain ScienceNational Research Center for Geriatrics and GerontologyObuJapan

Personalised recommendations